Bard1 Life Sciences Share Price and Company Fundamentals



Price
$2.48
Change
0.020 (0.813%)
52 week
0.57 - 5.6

Last traded: Today at 6:10 AM

BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.

Key Metrics

PE ratio

-

PB ratio

5.11

Dividend yield

Beta

-0.82

Market cap

$198.54M

Enterprise value

$192.1M

Company profile

Primary activitiesDeveloping and commercialising cancer diagnostic products.
Industry / SectorDiagnostics & Research / Healthcare
Websitehttp://www.bard1.com
Mailing address23 Normanby Road Notting Hill South Perth WA 3168 Australia
Phone / Fax61 3 9548 7586 /
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Bard1 Life Sciences does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Bard1 Life Sciences.

NameTitleAgeTotal Pay
Dr. Leearne Maree Hinch BSc., B.V.M.S., M.R.C.V.S., M.B.A.Chief Exec. Officer417.64k
Mr. Peter Lynton Gunzburg B Comm, ASIAManaging Director6882.12k
Mr. Tony Di Pietro AGIA, C.A., M.A.I.C.D., B.Com, CPACFO & Joint Company Sec.
Mr. Carl S. StubbingsChief Operating Officer
Dr. Peter William French M.B.A., B.Sc., M.Sc., Ph.D., MBA, FRSMChief Scientific Officer
Ms. Pauline Anne CollinsonJoint Company Sec.64

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-660.76%

Return on assets

-10.15%

Return on equity

-21.10%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Bard1 Life Sciences is 198.54M and its enterprise value is 192.1M. The enterprise value to revenue ratio of BD1 is 313.77.

Companies similar to Bard1 Life Sciences (BD1)

Bard1 Life Sciences (ASX:BD1) Frequently Asked Questions

1. What is Bard1 Life Sciences's Stock Symbol?

Bard1 Life Sciences trades on ASX under the ticker symbol "BD1".

2. What is Bard1 Life Sciences's stock price today?

One share of BD1 stock can currently be purchased for approximately $2.48.

3. How can I contact Bard1 Life Sciences?

Bard1 Life Sciences's mailing address is 23 Normanby Road Notting Hill South Perth WA 3168 Australia. The company can be reached via phone at 61 3 9548 7586.

4. What is Bard1 Life Sciences's official website?

The official website of Bard1 Life Sciences is http://www.bard1.com.

5. Which share registry manages Bard1 Life Sciences's stock?

Bard1 Life Sciences's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.